The first pick would be in the pharma space, we are seeing quite good momentum here today, so pharma you can see Syngene which is giving you a good fresh breakout above 700 level so I think it is looking quite positive from current levels to test higher targets of 720, 725.
HFCL’s AI, data centre exposure drives Nuvama’s Buy call; target implies 56% upside
Nuvama has initiated coverage on HFCL with a ‘Buy’ rating and a target price of Rs 380, implying a 56% upside from its reference price